Connect with us

Covid19

Information for Pediatric Healthcare Providers – Multisystem Inflammatory Syndrome in Children (MIS-C)

Avatar

Published

on

Who this is for: Pediatric Healthcare Providers

What this is for: To inform pediatric healthcare providers of information available on children with COVID-19.

How to use: Refer to this information when managing pediatric patients with confirmed or suspected COVID-19. For healthcare providers caring for neonates (≤28 days old), please refer to CDC guidance for evaluating and managing neonates at risk for COVID-19.

Nurse talks to new mother during an appointment.

Stay-at-home and shelter-in-place orders have resulted in declines in outpatient pediatric visits and fewer vaccine doses being administered, leaving children at risk for vaccine-preventable diseases. As states develop plans for reopening, healthcare providers are encouraged to work with families to keep or bring children up to date with their vaccinations. Primary care practices in communities affected by COVID-19 should continue to use strategies to separate well visits from sick visitsexternal icon. Examples could include:

  • Scheduling sick visits and well-child visits during different times of the day
  • Reducing crowding in waiting rooms, by asking patients to remain outside (e.g., stay in their vehicles, if applicable) until they are called into the facility for their appointment, or setting up triage booths to screen patients safely
  • Collaborating with healthcare providers in the community to identify separate locations for providing well visits for children

Healthcare providers should identify children who have missed well-child visits and/or recommended vaccinations and contact them to schedule in person appointments, starting with newborns, infants up to 24 months, young children and extending through adolescence. State-based immunization information systems and electronic health records may be able to support this work.

All newborns should be seen by a pediatric healthcare provider shortly after hospital discharge (3 to 5 days of age). Ideally, newborn visits should be done in person during the COVID-19 pandemic in order to evaluate for dehydration and jaundice, ensure all components of newborn screening were completed and appropriate confirmatory testing and follow-up is arranged, and evaluate mothers for postpartum depression. Developmental surveillance and early childhood screenings, including developmental and autism screening, should continue along with referrals for early intervention services and further evaluation if concerns are identified.

Burden of COVID-19 Among Children

Pediatric cases of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been reported. However, there are relatively fewer cases of COVID-19 among children compared to cases among adult patients.1-5

  • In the United States, 2% of confirmed cases of COVID-19 were among persons aged <18 years.4
  • In China, 2.2% of confirmed cases of COVID-19 were among persons aged <19 years old.1
  • In Italy, 1.2% of COVID-19 cases were among children aged <18 years.2
  • In Spain, 0.8% of confirmed cases of COVID-19 were among persons aged < 18 years.5

Among cases in children reported from China, most had exposure to household members with confirmed COVID-19.6-10

Clinical Presentation in Children

Symptoms in Pediatric Patients

Illness among pediatric cases appear to be mild, with most cases presenting with symptoms of upper respiratory infection such as:

  • Fever
  • Cough
  • Nasal congestion
  • Rhinorrhea
  • Sore throat

Outcomes in Pediatric Patients

Relatively few children with COVID-19 are hospitalized, and fewer children than adults experience fever, cough, or shortness of breath. Severe outcomes have been reported in children including COVID-19 associated deaths. Hospitalization was most common among pediatric patients aged <1 year and those with underlying conditions.

Although most cases reported among children to date have not been severe, clinicians should maintain a high index of suspicion for SARS-CoV-2 infection in children and monitor for progression of illness, particularly among infants and children with underlying conditions.

Incubation Period

While data on the incubation period for COVID-19 in the pediatric population are limited, it is thought to extend to 14 days, similar to adult patients with COVID-19.11 In studies from China, the reported incubation period among pediatric patients ranged from 2 to 10 days.7,12

Clinical Presentation

Pediatric patients with COVID-19 may experience the following signs or symptoms over the course of the disease:3,4,6,13-15

  • Fever
  • Cough
  • Nasal congestion or rhinorrhea
  • Sore throat
  • Shortness of breath
  • Diarrhea
  • Nausea or vomiting
  • Fatigue
  • Headache
  • Myalgia
  • Poor feeding or poor appetite

The predominant signs and symptoms of COVID-19 reported to date among all patients are similar to other viral respiratory infections, including fever, cough, and shortness of breath. Although these signs and symptoms may occur at any time during the overall disease course, children with COVID-19 may not initially present with fever and cough as often as adult patients.4,15,16 In a report of nine hospitalized infants in China with confirmed COVID-19, only half presented with fever.9 Gastrointestinal symptoms, including abdominal pain, diarrhea, nausea, and vomiting, were reported in a minority of adult patients.17 In one pediatric case of COVID-19, diarrhea was the only symptom reported.10

There have been multiple reports to date of children with asymptomatic SARS-CoV-2 infection.3,6,14,15 In one study, up to 13% of pediatric cases with SARS-CoV-2 infection were asymptomatic.16 The prevalence of asymptomatic SARS-CoV-2 infection and duration of pre-symptomatic infection in children are not well understood, as asymptomatic individuals are not routinely tested.

Signs and symptoms of COVID-19 in children may be similar to those for common viral respiratory infections or other childhood illnesses. It is important for pediatric providers to have an appropriate suspicion of COVID-19, but also to continue to consider and test for other diagnoses, such as influenza (see CDC’s Flu Information for Healthcare Professionals for more information).

Clinical Course and Complications in Children

The largest study of pediatric patients (>2,000) with COVID-19 from China reported that illness severity ranged from asymptomatic to critical:16

  • Asymptomatic (no clinical signs or symptoms with normal chest imaging): 4%
  • Mild (mild symptoms, including fever, fatigue, myalgia, cough): 51%
  • Moderate (pneumonia with symptoms or subclinical disease with abnormal chest imaging): 39%
  • Severe (dyspnea, central cyanosis, hypoxia): 5%
  • Critical (acute respiratory distress syndrome [ARDS], respiratory failure, shock, or multi-organ dysfunction): 0.6%

Based on these early studies, children of all ages are at risk for COVID-19; however, complications of COVID-19 appear to be less common among children compared with adults based on limited reports from China16 and the U.S.4,18 In children, SARS-CoV-2 may have more affinity for the upper respiratory tract (including nasopharyngeal carriage) than the lower respiratory tract.16

As of April 2, 2020, infants aged <1 year accounted for 15% of pediatric COVID-19 cases in the U.S.4 However, this age group remains underrepresented among COVID-19 cases in patients of all ages (0.3%) compared to their percentage in the U.S. population (1.2%). Relative to adult patients with COVID-19, there were fewer children with COVID-19 requiring hospitalization (6–20%) and ICU admission (0.6–2%).4 Although severe complications (e.g., acute respiratory distress syndrome, septic shock) have been reported in children of all ages,4,9,12,19 they appear to be infrequent. Based on limited data on children with either suspected or confirmed infection with SARS-CoV-2, infants (<12 months of age) may be at higher risk of severe or critical disease compared with older children,16 with hospitalization being most common among children aged <1 year and those with underlying conditions, such as chronic lung disease (including asthma), cardiovascular disease, and immunosuppression.4 Other reports describe a mild disease course, including in infants.7,9,16

In the United States, as of April 2, 2020, there have been three deaths among children with laboratory-confirmed SARS-CoV-2 infection that have been reported to CDC, but the contribution of SARS-CoV-2 infection to the cause of death in these cases is unclear.4

Multisystem Inflammatory Syndrome in Children (MIS-C)

CDC is collaborating with domestic and international partners to learn more about multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19.

Patients with MIS-C have presented with a persistent fever and a variety of signs and symptoms including multiorgan (e.g., cardiac, gastrointestinal, renal, hematologic, dermatologic, neurologic) involvement, and elevated inflammatory markers.

Healthcare providers who have cared or are caring for patients younger than 21 years of age meeting MIS-C criteria should report suspected cases to their local, state, or territorial health department. For more information including a full case definition, please visit MIS-C Information for Healthcare Providers.

Testing, Laboratory Findings, and Radiographic Findings

Diagnosis of COVID-19 requires detection of SARS-CoV-2 RNA by reverse transcription polymerase chain reaction (RT-PCR) testing. Testing strategies, including clinical criteria for considering testing and recommended specimen type, are the same for children and adults. CDC’s guidance for evaluation and management of neonates at risk for COVID-19 details specific testing considerations for newborns. For more information about testing, visit Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19), Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for COVID-19, and Frequently Asked Questions on COVID-19 Testing at Laboratories.

There are limited data on laboratory findings associated with COVID-19 in pediatric patients. Unlike adult patients with COVID-19,20,21 there have been no consistent leukocyte abnormalities reported in pediatric patients.22 Additional studies are required to understand the laboratory findings associated with pediatric cases of COVID-19.

Chest x-rays of children with COVID-19 have shown patchy infiltrates consistent with viral pneumonia, and chest CT scans have shown nodular ground glass opacities;14,23,24 however, these findings are not specific to COVID-19, may overlap with other diagnoses, and some children may have no radiographic abnormalities. Chest radiograph or CT alone is not recommended for the diagnosis of COVID-19. The American College of Radiology also does not recommend CT for screening or as a first-line test for diagnosis of COVID-19. (See American College of Radiology Recommendationsexternal icon)

Treatment and Prevention

Currently, there are no specific drugs approved by the U.S. Food and Drug Administration (FDA) for treatment or prevention of COVID-19. Treatment remains largely supportive and includes prevention and management of complications. Healthcare facilities, including pediatric healthcare facilities, should ensure that infection prevention and control policies, including universal source control, are in place to minimize chance of exposure to SARS-CoV-2 among providers, patients, and families. CDC has published specific guidance, including infection prevention and control considerations, for inpatient obstetric healthcare settings and the evaluation and management of neonates at risk for COVID-19.

The decision to manage a pediatric patient with mild to moderate COVID-19 in the outpatient or inpatient setting should be decided on a case-by-case basis. Pediatric healthcare providers should consider the patient’s clinical presentation, requirement for supportive care, underlying conditions, and the ability for parents or guardians to care for the child at home. For more information on home care of patients not requiring hospitalization visit: Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for Coronavirus Disease 2019 (COVID-19). There have been limited data on which underlying conditions in children might increase their risk of infection or disease severity. People of all ages, including children and adolescents, with certain underlying medical conditions such as chronic lung disease or moderate to severe asthma, serious heart conditions (e.g., congenital heart defects), immunocompromised conditions (e.g., cancer undergoing treatment), severe obesity (body mass index [BMI]≥40), diabetes, chronic kidney disease on dialysis or liver disease might be at higher risk for severe illness from COVID-19 and should be monitored for symptoms or signs of concern by their caregivers at home and by their clinical providers.

Severe complications associated with COVID-19 in pediatric patients have not been well-described. One newly described severe complication, multisystem inflammatory syndrome (MIS-C), is being investigated by CDC and partners. The treatment of severe and critical cases of pediatric patients with COVID-19 in the hospital may include management of pneumonia, respiratory failure, exacerbation of underlying conditions, sepsis or septic shock, or secondary bacterial infection. Situations in which a patient requires prolonged hospitalization may also result in secondary nosocomial infections.

Several organizations have published guidelines related to the treatment and management of COVID-19 patients, including pediatric patients:

For information regarding discontinuing transmission-based precautions and disposition of patients with COVID-19 in healthcare settings, please see: Discontinuation of Transmission-Based Precautions and Disposition of Patients with COVID-19 in Healthcare Settings (Interim Guidance).

Additional Information

References

  1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA
  2. Livingston E, Bucher K. Coronavirus Disease 2019 (COVID-19) in Italy. JAMA
  3. Su L, Ma X, Yu H, et al. The different clinical characteristics of corona virus disease cases between children and their families in China – the character of children with COVID-19. Emerging Microbes and Infection 2020; 9(1): 707-13.
  4. CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. MMWR Morbidity and Mortality Weekly Report. ePub: 6 April 2020. DOI: http://dx.doi.org/10.15585/mmwr.mm6914e4external icon.
  5. Tagarro A, Epalza C, Santos M, et al. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in Children in Madrid, Spain. JAMA Pediatr
  6. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis
  7. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis
  8. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223): 514-23.
  9. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang ZJ. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA
  10. Ji LN, Chao S, Wang YJ, et al. Clinical features of pediatric patients with COVID-19: a report of two family cluster cases. World journal of pediatrics : WJP
  11. Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med
  12. Sun D, Li H, Lu XX, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World journal of pediatrics : WJP
  13. Zheng F, Liao C, Fan QH, et al. Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China. Curr Med Sci
  14. Xu Y, Li, Xufang, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Medicine
  15. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. New England Journal of Medicine
  16. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics
  17. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA
  18. Team CC-R. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69(12): 343-6.
  19. Kamali Aghdam M, Jafari N, Eftekhari K. Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report. Infect Dis (Lond) 2020: 1-3.
  20. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med
  21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
  22. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med
  23. Chen F, Liu ZS, Zhang FR, et al. [First case of severe childhood novel coronavirus pneumonia in China]. Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; 58(3): 179-82.
  24. Feng K, Yun YX, Wang XF, et al. [Analysis of CT features of 15 Children with 2019 novel coronavirus infection]. Zhonghua er ke za zhi = Chinese journal of pediatrics 2020; 58(0): E007.

Source: https://tools.cdc.gov/api/embed/downloader/download.asp?m=403372&c=405573

Covid19

AllStar Health Brands Announces Updates on Covid Testing Initiatives

Avatar

Published

on

Miami, FL, April 2, 2021 – OTC PR WIRE — AllStar Health Brands Inc. (OTC Pink: ALST) (“AllStar Health” or the “Company”), a specialty pharmaceutical and nutritional supplements company, is pleased to update current and prospective shareholders on the status of the Company’s ON-Going Business Operations including Covid-19 testing Initiatives in several countries.

“As a Distributor for TPT Medtech, we are continuing to work in other countries including South Africa with the goal of introducing the ‘QuikPASS’ and ‘QuikLAB’ systems to offer definitive testing solutions in these countries,” stated Dr. Bagi, CEO of AllStar.

AllStar is a Distribution partner for TPT MedTech products and services in Jamaica. BayWest Wellness Center in Jamaica has contracted with TPT MedTech to utilize its “QuikPASS” and Check & Verify Passport technology systems at the Montego Bay Airport to verify that individuals have been tested to leave the county of Jamaica.  Baywest Wellness secured the Covid 19 testing contract with the Montego Bay Airport in February 2021 and executed its technology deal with TPT MedTech in February as well.

About AllStar Health Brands

AllStar Health Brands Inc. is a Nevada Corporation established in 2017, and headquartered in Miami, Florida. AllStar is a specialty HealthCare Products Company dedicated to improving health and quality of life by offering select, nutritional supplements, over the counter remedies, and medicines all across the Americas and Europe. AllStar’s goal is to bring additional products to the market and provide new, innovative options for better health and wellbeing.

For more information, please contact Investor Relations at (305) 423 7028.

Safe Harbor Statement

Statements about the Company’s future expectations and all other statements in this press release other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words “anticipate,” “estimate,” “expect,” “intend,” “plans,” “projects,” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties, and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.

SOURCE: AllStar Health Brands Inc.

Public Relations
EDM Media, LLC
https://edm.media
(800) 301-7883

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://otcprwire.com/allstar-health-brands-announces-updates-on-covid-testing-initiatives/

Continue Reading

Covid19

Enerkon Solar International (ENKS) Names New Board and Scientific Committee Members and Announces New FARA Filing in support of Commercial Aspirations

Avatar

Published

on

New York, April 1, 2021 – OTC PR WIRE – Enerkon Solar International (OTC PINK: ENKS) Names New Board and Scientific Committee Members and Announces today New FARA Filing in support of Commercial Aspirations in North Africa and other Important Updates regarding the new SARS2-COVID 15 Second “Insta-Test”.

ENKS Chairman Mr. Ballout stated that since the company Nominated a New Scientific Committee and Board Members this week, the company issue the first name selections today which are:

  • Senator Roberto Lario Rodriguez (Ret.) – (El Salvador) Advisory Bord Member for South and Central America
  • Dr Ibrahim El Nattar – (Egypt) Advisory Board Member for Renewable Energy in Africa
  • Dr Mark Schutz – Bioscience – (MD 0- USA), Graphene and Passive Immunity and Medical Advisory Board member
  • Michael Vishmidt (Israel/Ukraine) – Scientific Advisory Board Member for New Technology and Research
  • Dr Vasily Muraveynik, (Ukraine) – New Biomedical Science Advisory Board Member
  • Isaac Ray (Cal. USA) Special Scientific Advisor for Industrial Emission Suppression Technology
  • Nural KARAVELİOĞLU – (Turkey) – Consulting Board Member for Renewable Energy, Hydrogen and Government Relations”
  • Omar Mabruk Ilhayam (UK) – Advisory Board Member on Commerce and Energy for North Africa (Libya – Egypt – Algeria – Morocco – Tunisia) supporting Solar – Hydrogen – Energy Industry new Technology Transfer / Commercialization

Mr. Ballout Commented: “Our Great New Scientific and Regional Advisory Board will enhance Shareholder Value through supporting growth and expansion of ENKS and its Diverse Holdings – CVs and other information will be posted on the company website this week as well as other information on new opportunities and expansion plans.”

ENKS is comprised of 6 (Since the Sale of East Africa Unit to AL Fada Equity Holdings Last week)  -Companies, including corporate wholly or majority owned divisions – Corporate information for each will be posted on the company website for ease of search as some shareholders or investors have mentioned it was difficult to locate some of the data online, causing the possibility for others posting wrong or misleading information online –  therefore the company shall post additional legal documents and status information on line for all to have access”

Mr. Ballout Stated: “The company is proud of its New commercial relationship with companies and government personalities in Libya and Today, we have added an additional Statement of Registration with the US DOJ FARA National Security Division Agency for our work with the new, UNSMIL backed Government of Libya – This in support of our Compliance requirements for disclosure and in furtherance of our commercial aspirations in North Africa, related to Renewable Solar Energy, Hydrogen and other Commercial Interaction with the Region and in pre opposition to any Fake news, state clearly that the company has NO signed contracts with the government yet while we are hopeful that we will in the near future either via commercial entities or PPP structures we have for North Africa”.

“A technical call remains scheduled, with the new ChNPP director regarding the Chernobyl Special Exclusion Zone technical points and contents of this call which will be video recorded will explain better to the general public what Solar,  Co-Generation is (the use of Solar Power (about 500 MW or less to Power Electric Steam Boilers which in turn are planned to supply the pressure needed to drive the 3 Turbine Electric generators on the ChNPP Site whereby each generator has a tolerance of nearly 1 Gigawatt – and further auxiliary power from the solar array will power a 50 and later a 100MW Electrolysis Driven Green Hydrogen Plant to supply buyers of Green Hydrogen. The company, has already received expression of interest letters from German, Green Hydrogen Buyers and we shall post these letter(s) on the company website in coming days as well.”

Additional Support for the Modernization of the Ukraine Metals industry, will entail plans for Titanium Production and mining modernization – and Carbon Anode Sourcing for their Aluminum Industry – including Graphite Electrodes for their  Steel Industry modernization plans in the future (a letter from the Vice Prime minister of Ukraine regarding our cooperation on the Titanium Industry has already been received by the company some weeks ago – expressing appreciation and explaining the many jobs and social benefits of such cooperation to future development in Ukraine.

ENKS will Name a New Auditor Next Week once the File is Opened and Started for our last two years and current year Audit – in addition it is noted that this Auditor shall be retained on a continuous basis for all quarterly and Annual Reports in support of compliance requirements upon our planned up listing – this information will be added to the OTC Disclosures Site Page under Professional Service Providers (Auditor).

NEWS: Regarding the SARS2-COVID 15 Second “Insta-Test” device already produced for clinical trials and approvals (Owned by Graphene Leaders Canada and Distributed by KrowdX who has co sales agreements with the Coviklear International Holdings (UK) Unit Purchased before last week.

Mr. Ballout Stated:“ Great strides have been made in the development of the project supporting the commercialization of the SARS2-COVID Graphene Nanotech Based – 15 second “Insta-Test” – this being owned by GLC Canada and Distributed by KrowdX of Montreal – We are pleased to update that Pre Orders are due in very soon from ENKS /Coviklear partners abroad for the benefit of Krowdx and GLC to fulfill upon and after FDA Approval which is expected very soon (within just weeks as clinical trials of the already produced pre-production device is near completion during the next 10 days or so. – The Market for this device to Governments world wide cannot be understated, as it is the fastest test so far in the world and uses a much superior testing system, which takes only 15 seconds maximum time and uses a novel nanotech graphene biosensor to accomplish the amazing feat so fast, with such accuracy, (estimated at more than 97+ Percent) – Covillear Parent company  – ENKS also is in final talks with DGI in New York, for Financial Support to guarantee order fulfillment – supply chain management and other administrative support where needed, if asked to help, by the Owners and Distributors – This being our expression of confidence, as while we have already spent $5 Million USD to purchase Coviklear in a Debt Equity Swap before last week we are ready to engage much greater amounts of capital from our third party financial resources to support Factoring Order Fulfillment – Purchase order finance and other tools that may support the commercialization world wide for this groundbreaking disruptive Technology. It is noted that this is NOT a PCR test, and it does NOT use Reagents, or any chemicals whatsoever, its is based on electrical impedance using Nano Tech Graphene substrate, to send analysis to the device output at a very fast and high rate of efficacy – being far superior to PCR and similar tests, including all other DNS/RNA Tests – The test is NON-Invasive and safe.”

GLC Medical Inc. – Insta Test Initial Version

GLC Medical Inc. – Insta Test Updated Version

Governments and related PPPs / NGOs and others have expressed serious and immediate interest in ordering this new device which is now a reality, minus only its EUA (Emergency Use Application Green light at the FDA/HC and WHO) and this includes the KrowdX proprietary SES and STS solution for Airports – Sea Ports, Land Borders and other access and entry points between cities states provinces and otherwise to regain control of the Pandemic and free the world´s population again.

These details will be released by the Distributor KrowdX /Covikear, as they mutually agree, in the coming days/Week(s).

“Needless to say, the market value for this new device and technology is absolutely enormous, subject only to the contingencies mentioned above and we are absolutely excited about it all.”

“Stay Tuned for more updates on all of these new developments during the coming days and week(s)”

Lastly:

The Company expect to name an Auditor as previously mentioned above, during late next week if all goes well, in the company cost and – time – to – completion negotiations, going on now.

“Loyal ENKS Shareholders, are the ‘ENKS ARMY’, and the company will always support their best interests working to enhance shareholder value and steady growth.”

The foregoing statements are forward looking statements, and as such, they may or may not reflect the results which could transpire in the future which should be negative or not transpire at all due to circumstances or other reasons and investors, shareholders, or others should not rely on these forward-looking statements to ascertain any value if any of ENKS or to make any investment decisions and to take note that this is not an offer to buy or sell securities or an endorsement of ENKS for investment purposes as all investment carry a risk of loss sometimes a total loss of your investment in Micro cap shares markets or any market and therefore such statements or plans should not be relied upon for any business decisions of any kind – Approval and permissions required by federal regulations may or may not be approved and if not approved may result in the loss of all value and all investments in products requiring such regulatory permissions to market and sell. These statements are made as forward-looking statements for educational purposes only in accordance with the rules and regulations which pertain to the same.

Enerkon Solar International Inc.

www.enerkoninternational.com

info@enerkoninternational.com

New HQ Address in New York at:

Enerkon Solar International Inc

477 Madison Avenue

New York, NY 10022 USA

Tel. +1 (877) 573-7797

Tel. +1 (718) 709-7889

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://otcprwire.com/enerkon-solar-international-enks-names-new-board-and-scientific-committee-members-and-announces-new-fara-filing-in-support-of-commercial-aspirations/

Continue Reading

Blockchain

Qtum Partners with Vaccine Forward to Boost Global COVID-19 Vaccination Efforts

QTUM

The blockchain platform Qtum has announced the partnership with Vaccine Forward to help the fundraising initiative to raise vaccines for distribution to over 92 countries. The goal of the partnership is to raise $2 billion to speed the vaccination process through some of the world’s poorest countries, with the Qtum Chain Foundation committing to match […]

The post Qtum Partners with Vaccine Forward to Boost Global COVID-19 Vaccination Efforts appeared first on Blockonomi.

Avatar

Published

on

The blockchain platform Qtum has announced the partnership with Vaccine Forward to help the fundraising initiative to raise vaccines for distribution to over 92 countries.

The goal of the partnership is to raise $2 billion to speed the vaccination process through some of the world’s poorest countries, with the Qtum Chain Foundation committing to match the total number of vaccines raised by Vaccine Forward.

Vaccine Forward is a Swedish-based initiative aiming to fight this inequality having raised over 12k vaccinations ever since its start and has now looked for the support of the blockchain and crypto industry in collaboration with Qtum Chain Foundation, which has provided half of the total vaccinations.

Elisabeth Thand Ringqvist, Vaccine Forward founder, referred to the partnership by stating:

“As a grass-roots organization, Vaccine Forward is proud to receive the biggest donation so far, effectively doubling the amount of raised vaccinations, from 6 000 to 12 000 with Qtum’s donation. We are also very happy for Qtum’s challenge to the Blockchain-space at large to do the same.”

The organization depends on private and corporate donations to make it possible to help countries who need the vaccines to ensure the health of their citizens, which are distributed via the Global Vaccine Alliance (GAVI).

Soon, donors will also be able to contribute to this mission by making donations using cryptocurrency directly on Vaccine Forward’s website, facilitating the process for people around the world who might not be able to donate with fiat otherwise.

Crypto As a Tool for Equality

While developed countries have moved forward with vaccination efforts, countries with poor economies and strong political relationships have struggled to vaccinate their citizens, creating a high level of inequality among a pandemic that affects all countries equally.

One of the pillars of the crypto movement on its inception and till this day has been to provide people around the world with access to financial services and platforms without the need for centralized authorities having power over them, which has made crypto a lifeline for residents of countries under extreme poverty, dictatorships, or economic sanctions.

Cryptocurrency has been used by organizations like AirTm to help citizens from countries like Venezuela to receive economic assistance from people abroad by bypassing legal sanctions and economic restrictions placed by their country and foreign governments, highlighting some of the benefits of decentralization.

Similarly, projects designed to allow charities to receive donations from interested parties have also become increasingly popular in the crypto ecosystem, which has proven to be invaluable for charities over the last years.

Qtum Co-Founder, Jordan Earl, referred to the potential the industry has to help the transition out o the pandemic by saying:

“We hope that we can inspire our industry to do the same and also match Vaccine Forwards fundraising to help in the effort of vaccinating people who need it the most. We at Qtum are global problem solvers with an open platform and therefore, I think the grass-roots organization Vaccine Forward is an amazing solution to a complex global problem.”

The Qtum Ecosystem Continues to Grow

Qtum has experienced increasing success over the past year, which has not only been reflected by its cryptocurrency’s gain in value but also by the expansion of its ecosystem.

The most recent news came in the form of an announcement of its commitment to provide Filecoin with smart contracts capabilities through the Qtum network, something that while not only benefits users of the platform but also Qtum itself as part of its portfolio controls about 10% of Filecoin’s mining power.

Great Options for New Markets

Qtum is also looking into launching NFT support to compete against networks like Ethereum by offering lower prices, which has been an increasing pain for projects running on the Ethereum network.

With major networks like Cardano, Polkadot, and Ethereum getting closer to the release of their next updates, Qtum is looking forward to becoming a major competitor in the growing crypto ecosystem.

The network’s coin, QTUM, has gained over 700% in value over the last year according to Coingecko data, with a 90% over the last month which has seen most of the big projects in the crypto market go through a bearish trend.

1,274

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://blockonomi.com/qtum-partners-vaccine-forward/

Continue Reading

Covid19

France Imposes 3rd National Lockdown As COVID-19 Again Surges

Avatar

Published

on

Young people gathered Wednesday by the Seine River in Paris, largely without masks and without social distancing. French President Emmanuel Macron has ordered the country into a third lockdown because of the continued spread of COVID-19. Eleanor Beardsley/NPR hide caption

toggle caption

Eleanor Beardsley/NPR

PARIS – Calling the new, faster-spreading variants of the coronavirus “an epidemic within the epidemic,” French President Emmanuel Macron on Wednesday extended a lockdown to the entire country and closed schools through the end of April.

In a televised address to the nation, Macron said a “more dangerous, contagious and deadly” virus surging in France left him no choice.

“If we are choosing to close down the whole country it’s because no area of the country is spared,” Macron said. “Everywhere the virus is spreading faster and faster and everywhere, hospitalizations are rising.”

Gatherings inside and outside are also banned and people will not be allowed to travel more than 10 kilometers (6.2 miles) from their homes. Macron said unlike the first confinement last spring, people who leave their homes will not have to fill out a form with the time, date and purpose of their outing. “We are choosing to have confidence in people’s sense of responsibility,” he said.

“Everyone has to make sure not that they close themselves in, but that they limit, to the maximum, their contacts, meetings and time spent with others,” said Macron.

The president’s announcement was entirely anticipated. France’s intensive care units are at capacity with more than 5,000 COVID-19 patients health officials say, and hospitalizations have already surpassed the second wave of this past winter. They are on track to surpass even the first deadly wave of last spring.

Over the weekend, several dozen emergency room doctors signed an open letter in the newspaper Le Journal du Dimanche, warning that if something is not done, hospitals would soon have to begin choosing which patients receive treatment. “We cannot remain silent without betraying our Hippocratic oath,” they said.

Jacob Kirkegaard, who studies health care systems as a senior fellow with the German Marshall Fund, says the new strains of the virus are forcing countries to step up their public health measures. Britain, Germany and Italy are also in various forms of lockdown.

“When COVID cases in a country are suddenly much more contagious, the lockdowns need to be adjusted and made much tougher,” he said.

Kirkegaard said vaccinations in France have not yet increased to a level which would make a difference in transmission. Thirteen percent of the French have received one dose of a vaccine. Only 4% have been fully vaccinated. But Macron said the pace of vaccination would go faster very soon.

“We are putting all our means behind vaccinating, vaccinating, vaccinating,” he said, “on Saturday and Sunday just like during the week.” Macron said some 250,000 health professionals – doctors, pharmacists, veterinarians and fire fighters – will be involved in the massive vaccination effort across the country.

Over the last few warm, spring days, the banks of the Seine River in Paris have looked a lot like Venice Beach, Calif., with young people working-out and sunbathing, their masks under their chins. Macron said there will be patrols enforcing restrictions on alcohol consumption in public and plenty of fines given. Bars and restaurants have been closed since last fall.

Doctors say COVID-19 patients in France’s ICUs are younger and younger, often without any underlying health problems. Macron said 44% of patients in intensive care are younger than 65.

The country’s Scientific Council, which advises the government on measures to combat the virus, called for a strict lockdown in January. Macron defended his decision not to lock the country down then, saying people had benefitted from “precious weeks of liberty.”

But he said the accelerating pandemic propelled by new variants meant France had to set a new course for the coming months.

Writing of the gravity of the situation this week in the newspaper Libération, Patrick Bouet, president of the National Council of the Order of Doctors, called on Macron to institute stricter measures. “The virus is winning and we have lost control of the pandemic,” Bouet said.

France is now approaching 100,000 coronavirus deaths. “That’s the equivalent of wiping the city of Nancy from the map,” wrote Bouet.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.npr.org/2021/03/31/983157525/france-imposes-3rd-national-lockdown-as-covid-19-again-surges

Continue Reading
Esports2 days ago

Free Fire World Series APK Download for Android

Esports4 days ago

DreamHack Online Open Ft. Fortnite April Edition – How To Register, Format, Dates, Prize Pool & More

Esports4 days ago

Hikaru Nakamura drops chessbae, apologizes for YouTube strike

Fintech5 days ago

Australia’s Peppermint Innovation signs agreement with the Philippine’s leading micro-financial services provider

Esports2 days ago

Dota 2: Top Mid Heroes of Patch 7.29

Esports5 days ago

Coven and Abomination highlight the new TFT Reckoning Traits

Esports4 days ago

Apex Legends update 1.65 brings five new LTMs for War Games

Esports3 days ago

Ludwig Closes Out Month-Long Streaming Marathon in First Place – Weekly Twitch Top 10s, April 5-11

Esports3 days ago

Position 5 Faceless Void is making waves in North American Dota 2 pubs after patch 7.29

Blockchain5 days ago

Stock-to-Flow-Analyse: Bitcoin bei 288.000 USD

Esports3 days ago

Fortnite: Patch Notes v16.20 – Off-Road Vehicle Mods, 50-Player Creative Lobbies, Bug Fixes & More

Fintech5 days ago

SME finance platform offers advanced commission product

Blockchain4 days ago

Welche Probleme bringen US-Bitcoin ETFs mit sich?

Blockchain4 days ago

Which crypto exchange platform is faster, coin transfer or Godex?

Esports4 days ago

TenZ on loan to Sentinels through Valorant Challengers Finals

Esports4 days ago

Complete guide to romance and marriage in Stardew Valley

Esports4 days ago

Wild Rift patch 2.2a brings tons of champion changes and the addition of Rammus later this month

Esports4 days ago

flusha announces new CSGO roster featuring suNny and sergej

Esports4 days ago

Epic Games Store lost $181 million & $273 million in 2019 and 2020

Blockchain5 days ago

Bitcoin Preis Update: Wochenschlusskurs bei über 60.000 USD

Trending